CpG Island Methylator Phenotype and Prognosis of Colorectal Cancer in Northeast China

Abstract

Purpose. To investigate the association between CpG island methylator phenotype (CIMP) and the overall survival of sporadic colorectal cancer (CRC) in Northeast China. Methods. 282 sporadic CRC patients were recruited in this study. We selected MLH1, MGMT, p16, APC, MINT1, MINT31, and RUNX3 as the CIMP panel markers. The promoter methylation was assessed by methylation sensitive high resolution melting (MS-HRM). Proportional hazards-regression models were fitted with computing hazard ratios (HR) and the corresponding 95% confidence intervals (95% CI). Results. 12.77% (36/282) of patients were CIMP-0, 74.1% (209/282) of patients were CIMP-L, and 13.12% (37/282) of patients were CIMP-H. The five-year survival of the 282 CRC patients was 58%. There was significant association between APC gene promoter methylation and CRC overall survival (HR = 1.61; 95% CI: 1.05–2.46; P = 0.03). CIMP-H was significantly associated with worse prognosis compared to CIMP-0 (HR = 3.06; 95% CI: 1.19–7.89; P = 0.02) and CIMP-L (HR = 1.97; 95% CI: 1.11–3.48; P = 0.02), respectively. While comparing with the combine of CIMP-L and CIMP-0 (CIMP-L/0), CIMP-H also presented a worse prognosis (HR = 2.31; 95% CI: 1.02–5.24; P = 0.04). Conclusion. CIMP-H may be a predictor of a poor prognosis of CRC in Northeast China patients.

No association of CpG island methylator phenotype and colorectal cancer survival: population-based study

“…Results of previous studies on the role of chemotherapy in CIMP status subgroups were inconsistent. Li et al (2014) did not find an association between chemotherapy and OS for both CIMP-H and CIMP-L/N patients. Jover et al (2011) found that among stage II and III CRC patients chemotherapy was associated with significantly better DSS among CIMP-L/N patients (HR=0.4; 95% CI=0.2–0.6) but not among CIMP-H CRC patients (HR=0.8; 95% CI=0.3–2.0).…”

Long non-coding RNA LINC00858 promotes cells proliferation, migration and invasion by acting as a ceRNA of miR-22-3p in colorectal cancer

“…The incidence and mortality rate of CRC in China have increased rapidly over the past several decades [21]. In order to improve clinical prognosis of CRC patients, it is necessary to screen useful diagnostic and prognostic biomarkers of CRC, which can contribute to early diagnosis and improve the management of individualized treatment [22,23].…”

Methylator phenotype in colorectal cancer: A prognostic factor or not?

“…Six studies (Lee et al, 2008;Barault et al, 2008;Kim et al, 2009;Rhee et al, 2012;Li et al, 2014;Kang et al, 2015) showed a significant decrease in the OS of CIMP+ patients. The study of Barault et al (2008) showed no increase in the OS in the CIMP+ MSS and KRAS wild-type subgroup.…”